Clinical Trials Browser

Interventional × Skin Neoplasms × pembrolizumab × Clear all

NCT02621021 2026-04-20

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Phase 2/3 Recruiting

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Phase 2 Active not recruiting

26 enrolled 9 charts

Skin Neoplasms, Carcinoma, Merkel Cell

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Phase NA Recruiting

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Phase 3 Recruiting

Melanoma, Skin Neoplasms

NCT06295809 2026-03-27

INTerpath-007

Phase 2/3 Completed

Carcinoma, Squamous Cell, Skin Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT07436390 2026-03-02

MAK

Phase NA Completed

Melanoma, Skin Neoplasms

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

Melanoma, Skin Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Phase 1 Recruiting

DermatologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT05086692 2025-07-09

ABILITY-1

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT04301011 2025-04-23

RAPTOR

Phase 1 Terminated

DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Oropharyngeal Neoplasms, Skin Neoplasms

NCT05220748 2023-04-19

RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

Phase 1 Withdrawn

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Skin Neoplasms

NCT03684785 2022-04-07

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Phase 1/2 Terminated

Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell

NCT02521870 2021-08-03

SYNERGY-001

Phase 1/2 Terminated

241 enrolled 23 charts

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Melanoma, Skin Neoplasms

NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Phase 2 Terminated

132 enrolled 16 charts

Melanoma, Skin Neoplasms

NCT03666325 2018-09-11

I-Tackle

Phase 2 Unknown

Skin Neoplasms